ArticleOncoTargets and therapy2026
High-Dose Twice-Daily Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: A Real-World Retrospective Experience from Two Tertiary Centers.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperfractionated thoracic radiotherapy (RT) is a standard component of curative treatment for limited-stage small-cell lung cancer (LS-SCLC). While 45 Gy in 30 twice-daily fractions remains the most validated regimen, recent Phase II data suggest that dose-escalated RT using 60 Gy in 40 fractions may improve outcomes. However, real-world data on this intensified regimen remain scarce. Methods: We conducted a retrospective cohort study of LS-SCLC patients treated with 60 Gy in 40 twice-daily fractions and concurrent platinum-etoposide chemotherapy at two tertiary centers. Modern radiation techniques were employed. Key outcomes included overall survival (OS), progression-free survival (PFS), patterns of failure, and treatment-related toxicity. Results: Thirteen patients were included in the analysis. The median age at diagnosis was 59 years; 61.5% were female. At a median follow-up of 15 months, the 2-year OS rate was 71.4%, and the median OS was 30.9 months. The overall response rate was 60%. Most failures were distant; only one local failure was observed. Acute grade ≥3 esophagitis occurred in 7.6%, and no patients experienced grade ≥2 pneumonitis. Hematologic toxicity, particularly neutropenia, was frequent but manageable. No treatment-related deaths occurred. Conclusion: In this cohort, delivery of dose-escalated twice-daily thoracic radiotherapy using contemporary techniques was feasible and associated with acceptable toxicity in routine clinical practice. Survival outcomes were comparable to those reported in phase II studies of this approach. These findings warrant confirmation in larger, multi-institutional, or registry-based studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.